Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

IntroductionDrug repurposing is a promising strategy to develop new treatments for glioblastoma. In this phase II clinical trial, we evaluated the addition of chlorpromazine to temozolomide in the adjuvant phase of the standard first-line therapeutic protocol in patients with unmethylated MGMT gene...

Full description

Bibliographic Details
Main Authors: Andrea Pace, Giuseppe Lombardi, Veronica Villani, Dario Benincasa, Claudia Abbruzzese, Ilaria Cestonaro, Martina Corrà, Marta Padovan, Giulia Cerretti, Mario Caccese, Antonio Silvani, Paola Gaviani, Diana Giannarelli, Gennaro Ciliberto, Marco G. Paggi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
drug repurposing
chlorpromazine
adjuvant treatment
MGMT
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1320710/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1320710/full

Similar Items